Bicara Therapeutics
PublicBicara Therapeutics is now publicly traded
The data on this page reflects Bicara Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 16, 2024
Last Round
Series C
Dec 12, 2023
Total Funding Raised
$675M
Company Overview
Bicara Therapeutics, Inc. is a publicly traded, clinical-stage biopharmaceutical company that develops bifunctional therapies for solid tumors. Founded in 2018, the company's approach is to engineer biologics that combine the precision of tumor-targeting antibodies with the power of tumor microenvironment modulators. Its lead program, ficerafusp alfa (BCA101), is a first-in-class bifunctional antibody that targets both the epidermal growth factor receptor (EGFR) and transforming growth factor-beta (TGF-β). Ficerafusp alfa is in clinical development for several cancer types, with a primary focus on head and neck squamous cell carcinoma (HNSCC). The company is headquartered in Boston, Massachusetts, and trades on the Nasdaq under the symbol BCAX.
Sector
Consumer Products and Services (B2C)
AI Layer
Non-AI
Keywords
Bicara Therapeutics Comparables
Compare Bicara Therapeutics with similar companies based on industry and business-model similarity.
No public comparables are available for Bicara Therapeutics. Request access to learn about comparables coverage.
Request accessBicara Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 16, 2024 | ||||
| Series C | Dec 12, 2023 | ||||
| Series B | Mar 6, 2023 | ||||
| Seed | Mar 15, 2021 |
Key People
Founding team and executive leadership
Bicara Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series C |
| Janus Henderson Group | Series B, Series C |
| RA Capital Management | IPO, Series C, Series B |
| Omega Funds | Series B, Series C |
| Fairmont Capital | Series C |
| Braidwell | Series C |
| Heartland Healthcare Capital | Series B |
Bicara Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access